1[1]Pires LA, Wagshal AB, Lancey R, et al. Arrhythmias and conduction disturbance after coronary bypass graft surgery: epidemiology, managementand prognosis[J]. Am Heart J,1995,129:799.
2[2]Gill J,Heel CR, Fitton A. Amiodarone: An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmia[J]. Drugs 1992, 43:69.
3[3]Singh BH,Sarma JSM.Amiodarone and amiodarone derivatives. In:Singh BN,Dzau VJ. Vanhoutte PM.Woosley RL,eds. Cardiovascular Pharmacology and Therapeutics[M].New York: Churchill Livingstone,1994.689.
4[4]Clemo HF,Wood MA,Gilligan DM et al:Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias[J].Am J Cardiol, 1998,81:594.
5[5]Jafari-fesharaki M, Scheinman MM.Adverse effects of amio-darone[J]. Pace 1998,21:108.
6[6]Chow SS.Intravenous amiodarone:pharmacology,pharmacokinetics, and clinical use[J]. Ann Pharmacother,1996,30:637.
7[7]Olshansky B.Management of atrial fibrillation after coronaryartery bypass graft[J]. Am J Cardiol, 1996,78:27.
8[8]Kowey PR. Marinchak RA, Rials SJ, et al. Intravenous Amiodarone[J]. J Am Coll Cardiol, 1997,29:1190.
10[10]Scheinman MM, Levine JH,Cannom DS, et al . Dose ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrythmias[J]. Circulation, 1995,92:3264.
